# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Revolution Medicines, Inc. (NASDAQ:RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted canc...
Gainers Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) shares gained 188.8% to $4.13. The stock is now on the Regulation ...
Revolution Medicines Inc (NASDAQ: RVMD) has agreed to acquire EQRx Inc (NASDAQ: EQRX) in an all-stock transaction intended to a...
U.S. stocks traded lower, with the Nasdaq Composite falling around 70 points on Tuesday. Here are some big stocks recording gai...
Revolution Medicines, Inc. ("Revolution Medicines" or the "Company") (NASDAQ:RVMD), a clinical-stage oncology c...
Goldman Sachs analyst Chris Shibutani maintains EQRx (NASDAQ:EQRX) with a Neutral and lowers the price target from $5 to $3.